STW Biotech Stock
Reports & Analysis
OREX EP 4.14
SIGA EP 6.67
GNBT EP .36
- Will run to $23+ on
BARDA Contract-Buy 5-16-11
fell the day we made this recommendation along with most other small cap
biotech stocks and the overall market. If you took a position the afternoon
we made the GNBT recommendation you should have a great entry point of about
.36 giving you even more profit potential than we targeted.
GNBT stock has traded in this lower range between .35 and .37 for the past
week none of the factors that lead STW to pick GNBT have changed. We
reiterate our BUY Recommendation on GNBT.
This Weeks Stock Pick - Swing Trading Tip
6-7-2010 Trading Recommendation GNBT - Buy
Our penny stock swing trading tip for the week
6-7-2010 is a biotech stock we have watched for over a year and believe feel
is bottoming and reaching an oversold price in spite of several great bits
of news on its current FDA trials and pipeline. This
company is GNBT. It has recently bounced off a low in the .31 range and we
are building a position between .36 and .41 per share. The share
price trend is now moving up and we believe that the recent positive trials
and news will help shares of GNBT break thru resistance around .44 and when
that happens in the near future the share price will move back to the mid
.60ís giving a nice .20+ per share profit with a return near 50%.
The recent news on GNBT is positive interim results on Oral-Lyn spray Phase
III results could push GNBT towards the one dollar mark over the next few
months; and if the Phase III results result in FDA approval next year I expect a big move from
this stock because the Oral-Lyn spray that delivers insulin
through the inner lining of the cheek and results show that this is
superior to traditional insulin delivery methods being used by diabetics.
The Cancer program of GNBT is also showing promising results that have
just been presented at the prestigious 2010 ASCO meetings. GNBT has also
recently been granted several new patents and is beginning to receive cash
flow on foreign sales of some of its older programs.
We are long GNBT.
Here is the companies published overview and 1 year chart with some TA
GNBT - Generex Biotechnology Corporation is a development stage company in
the research, development, and commercialization of drug delivery systems
and technologies for metabolic and immunological diseases. It develops a
proprietary platform technology for the oral administration of large
molecule drugs, including proteins, peptides, monoclonal antibodies,
hormones, and vaccines. The companyís products include Generex Oral-lyn, an
insulin spray formulation used for the treatment of Type-1 and Type-2
diabetes; Glucose RapidSpray, which provides an alternative for people who
require additional glucose in their diet, as well as delivers glucose
formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy
spray designed to increase energy levels for sports, work, study, travel,
and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as
an aid for dieters. Generex Biotechnology Corporationís under development
products include medicinal chewing gum for the treatment of Type-2 diabetes
mellitus and obesity; morphine and fentanyl products for breakthrough and
postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase
II clinical trials for patients with HER-2/neu positive breast cancer. The
company markets its products through distributors and retail chains in
Ecuador, Canada, and the United States. It has collaboration with Fertin
Pharma A/S for the development of a metformin medicinal chewing gum. The
company was founded in 1983 and is based in Toronto, Canada.
Moving Average Price Compare GNBT is trading above its 13
day moving average. This is a bullish trend. There is added weight to this
indication because the moving average is rising and suggests that there is
buying interest in this stock.
Bollinger Bands GNBT is trading within its Bollinger Bands. This is a normal
condition and suggests that the stock is neither overbought nor oversold.
MACD GNBT is currently indicating a weak bullish signal.
On Balance Volume The On Balance Volume shows that longer term selling
pressure has given way to near term accumulation.
Directional Movement Index Today's trading has caused the +DI line to rise
above the -DI line. This is a bullish signal.
Stock Watch List